Overview of Patients

| **Characteristic** | **Remained on 3 or more drug classes, N = 6951** | **Switched to a 2-class regimen, N = 9281** |
| --- | --- | --- |
| **Age, years (IQR)** | 53.0 (48.0 to 59.0) | 53.0 (43.0 to 58.0) |
| **Male sex** | 492 (71%) | 675 (73%) |
| **Ethnicity** |  |  |
| White | 525 (76%) | 727 (79%) |
| Black | 128 (18%) | 136 (15%) |
| Other | 42 (6.0%) | 62 (6.7%) |
| **HIV transmission group** |  |  |
| MSM | 268 (39%) | 409 (44%) |
| HET | 257 (37%) | 339 (37%) |
| IDU | 119 (17%) | 129 (14%) |
| OTHER | 51 (7.3%) | 50 (5.4%) |
| **Pretreatment HIV viral load, log cp/mL (IQR)** | 12.1 (10.9 to 13.2) | 12.1 (10.6 to 13.2) |
| **Nadir CD4 count, cells/µL (IQR)** | 108 (38 to 209) | 168 (67 to 303) |
| **Median CD4 count, cells/µL (IQR)** | 556 (386 to 765) | 533 (357 to 746) |
| **Received NRTI monotherapy** | 358 (52%) | 310 (33%) |
| **Experienced virological failure** | 477 (69%) | 377 (41%) |
| **Resistance testing available** | 543 (78%) | 656 (71%) |
| **Median N of prior ART changes** | 10.0 (6.0 to 16.0) | 8.0 (3.0 to 13.0) |
| **Data source** |  |  |
| Cohort center | 494 (71%) | 492 (53%) |
| Hospital | 37 (5.3%) | 100 (11%) |
| Physician | 164 (24%) | 335 (36%) |
| **Median time since HIV diagnosis, years (IQR)** | 22.2 (14.7 to 27.4) | 16.7 (4.9 to 25.0) |
| **Median time since first ART, years (IQR)** | 19.3 (13.0 to 22.6) | 15.7 (5.5 to 20.8) |
| **Anchor agents** |  |  |
| Other | 320 (46%) | 297 (34%) |
| DRV DTG | 85 (12%) | 187 (22%) |
| DRV RGV | 42 (6.0%) | 79 (9.2%) |
| DRV EVG | 60 (8.6%) | 48 (5.6%) |
| ETV RGV | 36 (5.2%) | 66 (7.6%) |
| DRV ETV RGV | 54 (7.8%) | 38 (4.4%) |
| DTG RPV | 23 (3.3%) | 41 (4.8%) |
| DRV ETV | 35 (5.0%) | 26 (3.0%) |
| ATV DTG | 14 (2.0%) | 36 (4.2%) |
| ATV RGV | 14 (2.0%) | 25 (2.9%) |
| DRV NVP | 12 (1.7%) | 20 (2.3%) |
| **Baseline regimen includes booster** | 483 (69%) | 563 (65%) |
| 1Median (25% to 75%); n (%) | | |